pseudodeflectusin: was isolated from a culture broth of Aspergillus pseudodeflectus; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 10445309 |
| CHEMBL ID | 120182 |
| MeSH ID | M0480097 |
| Synonym |
|---|
| CHEMBL120182 |
| pseudodeflectusin |
| 9-hydroxy-7-methyl-2-propan-2-ylidene-7,9-dihydro-6h-furo[3,2-h]isochromen-3-one |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID146714 | Lethal dose against NUGC-3 human stomach cancer cell line | 2004 | Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13 | (4-Carboxamido)phenylalanine is a surrogate for tyrosine in opioid receptor peptide ligands. |
| AID86345 | Lethal dose against HeLa human cervix cancer cell line | 2004 | Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13 | (4-Carboxamido)phenylalanine is a surrogate for tyrosine in opioid receptor peptide ligands. |
| AID81663 | Lethal dose against HL-60 human peripheral blood cancer cell line | 2004 | Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13 | (4-Carboxamido)phenylalanine is a surrogate for tyrosine in opioid receptor peptide ligands. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.63) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||